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hEALth CARE RESOURCE UtILIzAtION AND mEDICAL COStS IN PAtIENtS 
WIth mULtIPLE SCLEROSIS
Yermakov S.1, Davis M.1, Calnan M.1, Fay M.2, Duh M.1, Iyer R.3
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Objectives: Prior studies have compared multiple sclerosis (MS) patients who are 
adherent to disease-modifying drug (DMD) therapy with those who are not, but have 
not analyzed the effect of varying levels of adherence on patient outcomes. This study 
characterized the benefits and cost offsets of increasing adherence to DMDs. Health 
care costs and resource use were assessed for patients with different adherence levels 
at various periods following DMD initiation. MethOds: A retrospective analysis was 
conducted using OptumHealth Reporting and Insights employer claims database 
on MS patients (≥ 2 diagnoses of ICD-9-CM 340.xx) initiating DMD therapy in 2002 
through Q1 2012. Direct medical costs (reimbursements to providers), indirect costs 
(disability payments and employer workloss costs), and resource use were analyzed 
in the six months prior to (baseline) and up to 36 months following (observation 
period) initiation. Adherence, persistence, and other outcomes were measured at 6, 
12, 24, and 36 months, and stratified by DMD adherence level. Results: 1,538 patients 
met the selection criteria (baseline age 43.6 years, 63% female). Adherence measured 
by proportion of days covered (PDC) declined from 82% at 6 months to 67% at 36 
months following initiation (medication possession ratio of 79% over the observation 
period). By 36 months, 42% of patients had discontinued DMD therapy; 22%, 31%, and 
47% of patients had PDC< 40%, 40% to 79%, and ≥ 80%, respectively. Non-DMD direct 
costs ($36,119, $30,277, and $25,886) and indirect costs ($23,194, $16,872, and $13,568) 
decreased substantially with higher adherence (PDC< 40%, 40% to 79%, and ≥ 80% at 36 
months, respectively). Higher adherence was also associated with lower all cause and 
MS-related inpatient admissions and emergency visits. Similar trends were observed 
at each follow-up period. cOnclusiOns: This study shows higher adherence to DMD 
therapies is associated with lower non-DMD medical and indirect costs and decreased 
health care resource use for MS patients.
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ADhERENCE Of mULtIPLE SCLEROSIS PAtIENtS tO DISEASE mODIfyING 
tREAtmENt AND ItS ImPACt ON QUALIty Of LIfE
Apecechea de Scheffer M., Faber S., Potthoff P., Eichmann F.
Kantar Health Germany, Munich, Germany
Objectives: Disease-modifying therapies (DMT) play an important part in the 
treatment of Multiple Sclerosis (MS). Non-Adherence to DMT affects therapy suc-
cess and thereby disturbs Health Related Quality of Life. The present study inves-
tigates patient adherence to approved DMTs for MS among geographically and 
culturally diverse patient populations and their impact on health related quality of 
life. MethOds: The study was an observational multinational post marketing study. 
2,566 patients 18 years or older with a documented diagnosis of relapsing-remitting 
MS (RRMS) and monotherapy with current DMT from Argentina, Australia, Austria, 
Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Iran, Ireland, 
Israel, Italy, Mexico, The Netherlands, Portugal, Spain, Sweden, Switzerland, UK, and 
Venezuela were included. Retrospective medical data about diagnosis and therapy 
were documented by physicians or nurses. For the purpose of patient reported 
outcome assessment, the MS International Quality of Life Questionnaire (MusiQoL) 
was selected. Results: “Adherence” was operationally defined as: “Not missing a 
DMT injection or changing dose within 4 week prior to study”. The study findings 
revealed that 75.0% of the patients were adherent. 12.6% of all patients forgot to 
administer injections compared to 50% of non-adherent patients.The most com-
mon reasons for non-adherence were forgetting to administer the injection, being 
tired of taking injections, pain at injection, and injection anxiety. Compared to non-
adherent patients, the disease history of adherent patients showed shorter disease 
duration (adherent: median 6 years; non-adherent: Median 7 years.), significantly 
shorter treatment time (30 months vs. 36 months; p< .001) and a better MusiQoL 
score (18.0 vs. 22.0; p< .001). cOnclusiOns: Non-adherence to DMTs affects QoL 
of MS-Patients. Special attention should be given to the causes for non-adherence. 
Reminder systems for injections can overcome the most frequent reason for non-
adherence.
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Objectives: MS is a chronic, progressive, autoimmune disease that is characterized 
by episodes of worsening symptoms or relapses. Patient adherence to medications 
can help reduce or lessen relapses; however, non-adherence is a recognized problem 
in patients with MS. The objectives of this study are to better understand patients’ 
reason(s) for switching and/or not being adherence to their medications. MethOds: 
We extracted 150 records for MS patients from a unique database of physician-
patient interactions (RealHealth Data). Using Atlas.ti, we analyzed these records to 
uncover trends for medication switches and/or non-adherence, i.e., when, why and 
how patients stopped, what if anything they took as a replacement or an addition as 
well as to the patients’ reaction(s) to new medication or non-medication. Results: 
On average, patients’ ages ranged from 18-45, 66% of patients reported their pain as a 
6 or 8 (on a scale out of 10) and 72% reported actively taking supplements in addition 
to their prescribed medications. Patients’ functional disability was similar to the 
general MS population, with a noted variability of motor skills. The medications pre-
scribed to these patients included: Aubagio (3%), Copaxone (22%), Extavia/Betaseron 
(15%), Gilenya (17%), Rebif (14%), Tecfidera (10%) and Tysabri (19%). Patients’ reported 
in health care consumed for the treatment of multiple sclerosis (MS) in patients 
enrolled in private (commercial) and publicly (Medicaid) funded health insurance 
programs. MethOds: In a retrospective analysis, integrated medical and phar-
macy claims data were analyzed to select patients with a diagnosis of MS (ICD-9 
code 340) during 2012 calendar year. The presence of comorbidities was also deter-
mined using ICD-9 codes present on medical claims. Prescription drug use was 
evaluated by pharmacy claims and drug-specific billing codes Results: 19,984 
patients with MS were identified, 18,269 from commercial payers and 1715 from 
Medicaid. Patients in the Medicaid group were younger (44.4 vs 48.8 years) and 
female (81.5% vs. 76.8%) compared to Commercial group, respectively. Although 
total annual costs related to the care of MS for the groups reflected a modest differ-
ence ($31,107 commercial; $33,344 Medicaid), costs associated with specific service 
categories varied greatly. Pharmacy costs were considerably less in the Medicaid 
group; however inpatient and emergency room costs were as much as 5 times 
higher. The lower pharmacy costs in the Medicaid group are related to lower use of 
disease-modifying treatments (DMTs); overall use of DMTs in the Medicaid group 
was seen in 32.5% of patients; while in the commercial patient group was 52.1%. 
Multivariate regression will be performed to examine the differences in cost and 
utilization adjusting for differences in baseline characteristics. cOnclusiOns: 
This analysis illustrates that notable variances exist in consumption of health care 
resources between patients enrolled in privately and publically funded health care 
programs. These variances may have additional implications relating to outcomes 
specific to MS.
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bAckgROund: Multiple studies have demonstrated the benefits of DMTs in slow-
ing disease progression; however cost of the DMTs is an issue given the current 
pricing pressures. This study evaluates the comparison of HRU and associated cost 
to provide the overall economic benefits of treatment with DMTs. Objectives: To 
compare populations, costs, and health care resource utilization (HRU) in patients 
with MultipleSclerosis (MS) treated with a disease modifying therapy (DMT) versus 
those who were not (Non-DMT). MethOds: A retrospective analysis of integrated 
medical and pharmacy claims data were analyzed inpatients with a diagnosis of 
MS (ICD -9 of 340.0) during 2012. There were 2 cohorts, those treated with a DMT 
and those not treated, (Non-DMT) for the entire 12 months by the presence or 
absence of relevant NDC and HCPCS codes. Results: 10,876 patients comprised 
the DMT cohort compared to 25,431 in the Non-DMT cohort. The two study groups 
were similar across a number of demographic variables including gender and age. 
When comparing HRU, significant differences were found in the DMT vs. Non-DMT 
treated groups. The unadjusted analysis showed that there was a 39.2% reduction 
in ER visits (15.68/100 vs. 24.25/100), a 35.9% reduction in MS related hospitaliza-
tions (46.64/100 vs. 76.62/100) and a 15.6% reduction in hospitalization length of 
stay (5.14 vs. 6.09), respectively. The average cost per patient for the DMT treated 
group was $61,698.16 ($33,983.87 due to DMT cost) compared to the total average 
cost per patient of $43,772.72 in the Non-DMT treated group. Multivariate regres-
sion will be performed to examine differences in cost and utilization adjusting for 
differences in baseline characteristics. cOnclusiOns: Although the total costs of 
treatment in the DMT group were substantially higher than in the Non-DMT group 
as expected, we found significantly beneficial reductions in HRU use that are costly 
drivers in health care.
PND33
DRIvERS Of UtILIzAtION AmONG PAtIENtS WIth mUCOPOLySACChARIDOSIS 
IN thE hOSPItAL SEttING
Belk K.W., Craver C.W.
MedAssets, Charlotte, NC, USA
Objectives: Mucopolysaccharidosis (MPS) is a rare metabolic disorder with a wide 
spectrum of symptoms affecting the bone, skeletal system, and organs of affected 
individuals. The severity of symptoms varies widely. The objective of this study is 
to examine drivers of hospital utilization in MPS patients. MethOds: A retrospec-
tive descriptive study was conducted on a cross-section of MPS discharges in the 
MedAssets health system data for inpatient (N= 527) and outpatient (N= 10450) 
visits from 2009 through 2013. Negative binomial multivariable regression was 
used to identify significant drivers of inpatient and outpatient visits and inpatient 
length of stay (LOS). Results: The sample included 1454 unique patients from 216 
hospitals. More than half of thedischarges (66.7%) were male with 87.3% less than 
18 years old and 8.7% between the ages of 18 and 29. The most common comorbid 
conditions in inpatients were chronic obstructive pulmonary disease (27.1%), res-
piratory failure (24.1%), pneumonia (20.5%), heart valve disorders (18.6%), epilepsy 
and seizures (17.8%), and hypertension (16.1%). In outpatients the most common 
comorbidities were delayed mental development (7.9%), musculoskeletal disor-
ders (6.9%), hypertension (6.9%), and heart valve disorders (5.7%). The average 
number of outpatient visits was 7.1 with primary drivers including esophageal 
reflux (IRR= 1.73, p< .001), lack of development (IRR= 1.69, p< .001), gastrointestinal 
issues (IRR= 1.47, p< .01), and hydrocephalus (IRR= 1.52, p< .05). While the average 
number of inpatient visits was less than 1 the average LOS was 11.47. Respiratory 
failure (IRR= 1.58, p< .001) and vein disorders (IRR= 1.71, p< .01) were associated 
with inpatient visits. In addition to teaching status and region drivers of LOS were 
hypertension (IRR= 1.64, p< .001), respiratory failure (IRR= 1.50, p< .01), cardiovas-
cular disorders (IRR= 3.91, p< .01), pneumonia (IRR= 1.40, p< .05), and vein disorders 
(IRR= 1.71, p< .05). cOnclusiOns: MPS patients average more than one outpatient 
visit per year and when hospitalized have long LOS. Drivers of utilization vary in 
the inpatient and outpatient setting.
